evolocumabalirocumabtertiary hospital
…Background and Importance PCSK9 inhibitors (alirocumab and evolocumab) effectively reduce Low-density lipoprotein (LDLc) and cardiova…
9articles mentioning drugs
23drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Evolocumab ×
Evolocumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Evolocumab
9 articles · page 1 of 1bempedoic acidicosapent ethylevolocumabinclisiranalirocumab
…th the greatest reductions in LDL-C, followed by inclisiran and bempedoic acid.…
evolocumabezetimibeAISTriple therapylarge vessel occlusion (LVO)acute ischemic stroke
… adverse events of intensive lipid-lowering treatment including evolocumab and ezetimibe (triple therapy) after endovascular thrombectomy …
99.1%
inclisiranevolocumabalirocumabatorvastatinrosuvastatinperipheral arterial diseaseischaemic heart diseaseischaemic cerebrovascular diseaseheterozygous familial hypercholesterolaemiaHeFH+2 more
…itors (PCSK9 inhibitors), including evolocumab, alirocumab, and inclisiran, are potent lipid-lowering agents indicated for patients at hig…
evolocumabezetimibeevolucumabalirocumabrosuvastatinatorvastatinsecondary cardiovascular events or strokes
…ilisin/kexin type 9 inhibitors (PCSK9i), such as alirocumab and evolocumab, effectively manage cLDL levels. However, the relative efficacy…
evolocumabcoronary artery diseaseCardiovascular (CV) diseasecerebrovascular diseaseperipheral artery disease
…rden of this population globally are not known. The benefits of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in …
evolocumabalirocumabPCSK9iezetimibebempedoic acidhypercholesterolaemiatertiary care hospital
…s with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material an…
inclisiranalirocumabezetimibeevolocumabfenofibratestatinbempedoic acidischaemic heart diseaseprimary hypercholesterolaemia
…isease, and three with familial hypercholesterolaemia. Prior to inclisiran, 11 patients (28.9%) had been treated with evolocumab and 2 pat…
inclisiranevolocumabalirocumabbococizumabtafolecimabPCSK9iatherosclerotic cardiovascular diseaseFamilial hypercholesterolaemia (FH)
… including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (…